Skip to main content
PMC home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2014 Mar 18;10(1):1–7. doi: 10.1007/s10156-003-0296-9

Current concepts in SARS treatment

Takeshi Fujii 1,*, Aikichi Iwamoto 1, Tetsuya Nakamura 2, Aikichi Iwamoto 2
PMCID: PMC7088022  PMID: 14991510

Abstract

The outbreak of severe acute respiratory syndrome (SARS) has drawn enormous attention and caused fear worldwide since early 2003. The disease appears to be under control now; however, the possible return of SARS must be emphasized. Although many clinical experiments have been reported, the treatment of SARS is largely anecdotal, and so far no treatment consensus has been reached. We summarize 14 clinical reports and attempt to assess the effectiveness of various treatment regimens. A combination treatment of steroids and ribavirin was widely used empirically from the outset of the epidemic. In general, the use of steroids for SARS seemed beneficial, but the optimal timing, dosage, and duration of treatment have not yet been determined. On the other hand, ribavirin administration apparently reduced neither the rate of intratracheal intubation nor that of mortality. Moreover, significant toxicity, such as hemolytic anemia, has been attributed to ribavirin. A few preliminary trials and in vitro data suggest the possibility of treating SARS with interferon. Other agents, including the HIV protease inhibitor glycyrrhizin and convalescent plasma, remain to be evaluated.

Key words: SARS, Treatment, Steroids, Ribavirin, Interferons

References

  • 1.Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976. doi: 10.1056/NEJMoa030747. [DOI] [PubMed] [Google Scholar]
  • 2.Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–1966. doi: 10.1056/NEJMoa030781. [DOI] [PubMed] [Google Scholar]
  • 3.Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319–1325. doi: 10.1016/S0140-6736(03)13077-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Zhong N.S., Zheng B.J., Li Y.M., Poon L.L., Xie Z.H., Chan K.H., et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet. 2003;362:1353–1358. doi: 10.1016/S0140-6736(03)14630-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.World Health Organization . World Health Organization; Geneva: 2003. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 (revised 26 September 2003) [Google Scholar]
  • 6.Poon L.L., Chan K.H., Wong O.K., Yam W.C., Yuen K.Y., Guan Y., et al. Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol. 2003;28:233–238. doi: 10.1016/j.jcv.2003.08.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ng E.K., Hui D.S., Chan K.C., Hung E.C., Chiu R.W., Lee N., et al. Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem. 2003;49:1976–1980. doi: 10.1373/clinchem.2003.024125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Peiris J.S., Chu C.M., Cheng V.C., Chan K.S., Hung I.F., Poon L.L., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767–1772. doi: 10.1016/S0140-6736(03)13412-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Labro M.T., Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother. 2001;13:3–8. doi: 10.1179/joc.2001.13.1.3. [DOI] [PubMed] [Google Scholar]
  • 10.Dalhoff A., Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003;3:359–371. doi: 10.1016/s1473-3099(03)00658-3. [DOI] [PubMed] [Google Scholar]
  • 11.Fouchier R.A., Kuiken T., Schutten M., van Amerongen G., van Doornum G., van den Hoogen B.G., et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature. 2003;423:240. doi: 10.1038/423240a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Tsang K.W., Ho P.L., Ooi G.C., Yee W.K., Wang T., Chan-Yeung M., et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1977–1985. doi: 10.1056/NEJMoa030666. [DOI] [PubMed] [Google Scholar]
  • 13.Lee N., Hui D., Wu A., Chan P., Cameron P., Joynt G.M., et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1986–1994. doi: 10.1056/NEJMoa030685. [DOI] [PubMed] [Google Scholar]
  • 14.Poutanen S.M., Low D.E., Henry B., Finkelstein S., Rose D., Green K., et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348:1995–2005. doi: 10.1056/NEJMoa030634. [DOI] [PubMed] [Google Scholar]
  • 15.Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801–2809. doi: 10.1001/jama.289.21.JOC30885. [DOI] [PubMed] [Google Scholar]
  • 16.So L.K., Lau A.C., Yam L.Y., Cheung T.M., Poon E., Yung R.W., et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet. 2003;361:1615–1617. doi: 10.1016/S0140-6736(03)13265-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lapinsky S.E., Hawryluck L. ICU management of severe acute respiratory syndrome. Intensive Care Med. 2003;29:870–875. doi: 10.1007/s00134-003-1821-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Lamberts S.W., Bruining H.A., de Jong F.H. Corticosteroid therapy in severe illness. N Engl J Med. 1997;337:1285–1292. doi: 10.1056/NEJM199710303371807. [DOI] [PubMed] [Google Scholar]
  • 19.Bernard G.R., Luce J.M., Sprung C.L., Rinaldo J.E., Tate R.M., Sibbald W.J., et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317:1565–1570. doi: 10.1056/NEJM198712173172504. [DOI] [PubMed] [Google Scholar]
  • 20.Meduri G.U., Headley A.S., Golden E., Carson S.J., Umberger R.A., Kelso T., et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280:159–165. doi: 10.1001/jama.280.2.159. [DOI] [PubMed] [Google Scholar]
  • 21.Popara M., Pendle S., Sacks L., Smego R.A., Jr., Mer M. Varicella pneumonia in patients with HIV/AIDS. Int J Infect Dis. 2002;6:6–8. doi: 10.1016/s1201-9712(02)90128-1. [DOI] [PubMed] [Google Scholar]
  • 22.Ito I., Ishida T., Hashimoto T., Arita M., Osawa M., Tsukayama C. Familial cases of severe measles pneumonia. Intern Med. 2000;39:670–674. doi: 10.2169/internalmedicine.39.670. [DOI] [PubMed] [Google Scholar]
  • 23.Lauer G.M., Walker B.D. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52. doi: 10.1056/NEJM200107053450107. [DOI] [PubMed] [Google Scholar]
  • 24.McCormick J.B., King I.J., Webb P.A., Scribner C.L., Craven R.B., Johnson K.M., et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986;314:20–26. doi: 10.1056/NEJM198601023140104. [DOI] [PubMed] [Google Scholar]
  • 25.Wyde P.R. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res. 1998;39:63–79. doi: 10.1016/s0166-3542(98)00029-1. [DOI] [PubMed] [Google Scholar]
  • 26.Sidwell R.W., Huffman J.H., Campbell N., Allen L.B. Effect of ribavirin on viral hepatitis in laboratory animals. Ann N Y Acad Sci. 1977;284:239–246. doi: 10.1111/j.1749-6632.1977.tb21956.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ning Q., Brown D., Parodo J., Cattral M., Gorczynski R., Cole E., et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol. 1998;160:3487–3493. [PubMed] [Google Scholar]
  • 28.Koren G., King S., Knowles S., Phillips E. Ribavirin in the treatment of SARS: a new trick for an old drug? CMAJ. 2003;168:1289–1292. [PMC free article] [PubMed] [Google Scholar]
  • 29.Zhao Z., Zhang F., Xu M., Huang K., Zhong W., Cai W., et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003;52:715–720. doi: 10.1099/jmm.0.05320-0. [DOI] [PubMed] [Google Scholar]
  • 30.Hsu L.Y., Lee C.C., Green J.A., Ang B., Paton N.I., Lee L., et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis. 2003;9:713–717. doi: 10.3201/eid0906.030264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Nicholls J.M., Poon L.L., Lee K.C., Ng W.F., Lai S.T., Leung C.Y., et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361:1773–1778. doi: 10.1016/S0140-6736(03)13413-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Choi K.W., Chau T.N., Tsang O., Tso E., Chiu M.C., Tong W.L., et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med. 2003;139:715–723. doi: 10.7326/0003-4819-139-9-200311040-00005. [DOI] [PubMed] [Google Scholar]
  • 33.WHO issues consensus document on the epidemiology of SARS. Wkly Epidemiol Rec. 2003;78:373–375. [PubMed] [Google Scholar]
  • 34.Wong G.W., Hui D.S. Severe acute respiratory syndrome (SARS): epidemiology, diagnosis and management. Thorax. 2003;58:558–560. doi: 10.1136/thorax.58.7.558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Tsang K.W., Lam W.K. Management of severe acute respiratory syndrome: the Hong Kong University experience. Am J Respir Crit Care Med. 2003;168:417–424. doi: 10.1164/rccm.2305012. [DOI] [PubMed] [Google Scholar]
  • 36.Ho J.C., Ooi G.C., Mok T.Y., Chan J.W., Hung I., Lam B., et al. High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med. 2003;168:1449–1456. doi: 10.1164/rccm.200306-766OC. [DOI] [PubMed] [Google Scholar]
  • 37.Wang H., Ding Y., Li X., Yang L., Zhang W., Kang W. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med. 2003;349:507–508. doi: 10.1056/NEJM200307313490519. [DOI] [PubMed] [Google Scholar]
  • 38.Cyranoski D. Critics slam treatment for SARS as ineffective and perhaps dangerous. Nature. 2003;423:4. doi: 10.1038/423004a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361:2045–2046. doi: 10.1016/S0140-6736(03)13615-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Hultgren C., Milich D.R., Weiland O., Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol. 1998;79(Pt 10):2381–2391. doi: 10.1099/0022-1317-79-10-2381. [DOI] [PubMed] [Google Scholar]
  • 41.Zhaori G. Antiviral treatment of SARS: can we draw any conclusions? CMAJ. 2003;169:1165–1166. [PMC free article] [PubMed] [Google Scholar]
  • 42.Jordan L.T., Derbyshire J.B. Antiviral activity of interferon against transmissible gastroenteritis virus in cell culture and ligated intestinal segments in neonatal pigs. Vet Microbiol. 1994;38:263–276. doi: 10.1016/0378-1135(94)90007-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Fuchizaki U., Kaneko S., Nakamoto Y., Sugiyama Y., Imagawa K., Kikuchi M., et al. Synergistic antiviral effect of a combination of mouse interferon-alpha and interferon-gamma on mouse hepatitis virus. J Med Virol. 2003;69:188–194. doi: 10.1002/jmv.10286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Pitkaranta A., Nokso-Koivisto J., Jantti V., Takala A., Kilpi T., Hovi T. Lowered yields of virus-induced interferon production in leukocyte cultures and risk of recurrent respiratory infections in children. J Clin Virol. 1999;14:199–205. doi: 10.1016/S1386-6532(99)00056-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Treatment of SARS with human interferons. Lancet. 2003;362:293–294. doi: 10.1016/S0140-6736(03)13973-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Antonelli G., Scagnolari C., Vicenzi E., Clementi M. Treatment of SARS with human interferons [letter] Lancet. 2003;362:1158. doi: 10.1016/S0140-6736(03)14482-0. author reply 1158-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Moriguchi H., Sato C. Treatment of SARS with human interferons [letter] Lancet. 2003;362:1159. doi: 10.1016/S0140-6736(03)14484-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wang J., Liu P., Chen W., Yin S., Jiang S., Yan L., et al. A hospital outbreak of severe acute respiratory syndrome in Guangzhou. China. Chin Med J (Engl) 2003;116:811–818. [PubMed] [Google Scholar]
  • 49.Loutfy MR, Blatt L, S W. Preliminary results on the potential therapeutic benefit of interferon alfacon-1 plus steroids in severe acute respiratory syndrome [Abstract]. 43rd Annual Interscience Conference of Antimicrobial Agents and Chemotherapy; 2003 Sep 13-17; Chicago, IL, USA.
  • 50.Sung J. Clinical diagnosis and management of SARS. Proceedings of the WHO Global Conference on Severe Acute Respiratory Syndrome (SARS); 2003 Jun 17-18; Kuala Lumpur, Malaysia.
  • 51.Xiao Z., Li Y., Chen R., Li S., Zhong S., Zhong N. A retrospective study of 78 patients with severe acute respiratory syndrome. Chin Med J (Engl) 2003;116:805–810. [PubMed] [Google Scholar]
  • 52.Fowler R.A., Lapinsky S.E., Hallett D., Detsky A.S., Sibbald W.J., Slutsky A.S., et al. Critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290:367–373. doi: 10.1001/jama.290.3.367. [DOI] [PubMed] [Google Scholar]
  • 53.Tsui P.T., Kwok M.L., Yuen H., Lai S.T. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg Infect Dis. 2003;9:1064–1069. doi: 10.3201/eid0909.030362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Chan J.W., Ng C.K., Chan Y.H., Mok T.Y., Lee S., Chu S.Y., et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS) Thorax. 2003;58:686–689. doi: 10.1136/thorax.58.8.686. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Infection and Chemotherapy are provided here courtesy of Elsevier

RESOURCES